Kawada Y, Shimizu Y, Horie M, Tokuyama H, Matsuda S, Nishiura T
Jpn J Antibiot. 1984 Mar;37(3):285-9.
The predisposing factors of funguria and the clinical efficacy of treatment with ketoconazole, a new oral imidazole antifungal drug were studied in 10 patients with complicated urinary tract infection due to fungi. Preceding antibiotic therapy, presence of indwelling catheter and malignant tumor were regarded as the important factors that predisposed to the fungal urinary tract infections. Patients received 200 mg of ketoconazole once a day for 5 to 14 days. Of the 9 patients in whom clinical efficacy of ketoconazole was evaluated, excellent response was obtained in 4 patients, moderate in 2 and poor in 3 patients. Of the 9 strains of fungi isolated before treatment, 6 strains or 67% were eradicated after treatment. Neither subjective nor objective side effects were observed in any of 10 patients receiving ketoconazole, and laboratory tests showed elevated BUN and serum creatinine in 1 patient. From the results obtained in this study, ketoconazole was regarded as useful in the treatment of complicated urinary tract infection due to fungi.
对10例因真菌引起的复杂性尿路感染患者，研究了真菌尿的诱发因素及新型口服咪唑类抗真菌药酮康唑的治疗临床疗效。抗生素治疗史、留置导尿管及恶性肿瘤被视为易发生真菌性尿路感染的重要因素。患者每天服用200mg酮康唑，持续5至14天。在评估酮康唑临床疗效的9例患者中，4例反应良好，2例中等，3例较差。治疗前分离出的9株真菌中，6株（67%）在治疗后被清除。接受酮康唑治疗的10例患者均未观察到主观或客观副作用，实验室检查显示1例患者血尿素氮和血清肌酐升高。根据本研究结果，酮康唑被认为对治疗因真菌引起的复杂性尿路感染有效。
